8-K: Assertio Holdings Reports Mixed Q2 2024 Results; Rolvedon Sales Grow, Indocin Declines

Assertio Holdings announced its second quarter 2024 financial results, highlighting growth in Rolvedon sales but a decrease in Indocin sales due to generic competition.

Summary

• Assertio Holdings reported a net product sales of $30.7 million for the second quarter of 2024, compared to $31.9 million in the first quarter of 2024 and $40.1 million in the second quarter of 2023.
• The company experienced a net loss of $3.7 million, or $0.04 per share, for the second quarter of 2024, compared to a net loss of $4.5 million, or $0.05 per share, in the first quarter of 2024 and a net income of $8.5 million, or $0.13 per share, in the second quarter of 2023.
• Adjusted EBITDA for the second quarter was $5.0 million, down from $7.4 million in the first quarter and $24.8 million in the second quarter of 2023.
• Rolvedon net product sales increased to $15.1 million in the second quarter, up from $14.5 million in the first quarter, driven by volume growth.
• Indocin net product sales decreased to $6.9 million in the second quarter, down from $8.7 million in the first quarter, due to generic competition.
• The company generated $7.4 million in cash flow from operations in the second quarter, compared to $7.5 million in the first quarter.
• Cash and short-term investments increased to $88.4 million at the end of the second quarter, up from $80.7 million at the end of the first quarter.
• Assertio reiterated its full-year 2024 guidance for net product sales between $110.0 million and $125.0 million and adjusted EBITDA between $20.0 million and $30.0 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While Rolvedon shows positive growth, the overall financial results are mixed with a net loss and decreased EBITDA. The impact of generic competition on Indocin sales is a concern, but the company's cash position and reaffirmed guidance provide some stability.

Positives

• Rolvedon sales continue to grow, demonstrating strong market acceptance and demand.
• The company's cash position has improved, providing financial flexibility.
• Assertio is generating positive cash flow from operations.
• The completion of enrollment for the Rolvedon same-day dosing trial is a positive step for future product differentiation.
• The company has reiterated its full-year financial guidance, indicating confidence in its performance.

Negatives

• Net product sales decreased to $30.7 million in Q2 2024 from $31.9 million in Q1 2024 and $40.1 million in Q2 2023.
• The company reported a net loss of $3.7 million in Q2 2024.
• Adjusted EBITDA decreased to $5.0 million in Q2 2024 from $7.4 million in Q1 2024.
• Indocin sales declined to $6.9 million in Q2 2024 due to generic competition.
• Gross margin decreased to 73% from 78% when excluding Rolvedon purchase accounting inventory step-up amortization, primarily due to increased inventory write-downs and a change in product mix.

Risks

• The company faces risks related to generic competition for its products, particularly Indocin.
• There are risks associated with the successful commercialization and market acceptance of Rolvedon and other products.
• The company's financial results could be impacted by pricing pressures and managed healthcare practices.
• Assertio relies on third-party manufacturers and single-source suppliers, which could disrupt its supply chain.
• The company is involved in various legal proceedings and government investigations, which could result in significant costs and liabilities.
• The company's stock price has been trading near the Nasdaq minimum bid requirement, which could lead to delisting if not maintained.

Future Outlook

Assertio has reiterated its full-year 2024 guidance, projecting net product sales between $110.0 million and $125.0 million and adjusted EBITDA between $20.0 million and $30.0 million. The company also anticipates presenting initial data from the Rolvedon same-day dosing trial at a medical conference later this year.

Management Comments

• Brendan O'Grady, the CEO, stated he is excited to work with the team and focus on maximizing results.
• He highlighted the company's focus on driving the financial performance of key assets like Rolvedon, generating cash flow, and identifying new assets to create further value for stockholders.
• He noted that Rolvedon has been well received by physicians and continues to increase its market share.

Industry Context

The pharmaceutical industry is facing increasing generic competition, which is impacting the sales of established products like Indocin. Assertio's focus on growing Rolvedon sales and developing new assets is a strategic response to these challenges. The company's performance is also influenced by pricing pressures and managed healthcare practices, which are common trends in the industry.

Comparison to Industry Standards

• Assertio's performance is mixed when compared to industry standards.
• While Rolvedon's growth is a positive sign, the decline in Indocin sales due to generic competition is a common challenge faced by pharmaceutical companies with off-patent drugs.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) have faced similar challenges with generic erosion of their branded products.
• Assertio's adjusted EBITDA of $5.0 million for the quarter is lower than some of its peers, but the company's focus on cash flow generation is a positive sign.
• The company's gross margin of 71% is within the range of other specialty pharmaceutical companies, but the decrease when excluding Rolvedon purchase accounting inventory step-up amortization is a concern.
• Companies like Horizon Therapeutics and Jazz Pharmaceuticals have shown strong growth in their specialty product portfolios, which Assertio is aiming to replicate with Rolvedon.

Legal Proceedings

• The company is involved in various legal proceedings and government investigations, including pending and potential future shareholder litigation relating to the Spectrum Merger and/or the recent approval and launch of generic indomethacin suppositories, antitrust litigation, opioid-related government investigations and opioid-related litigation, the recently unsealed qui tam litigation, as well as Spectrums legacy shareholder and other litigation and, and other disputes and litigation.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased EBITDA, but the growth of Rolvedon and the company's cash position are positive signs.
• Employees may be affected by the company's restructuring plans and the need to adapt to changing market conditions.
• Customers, particularly oncology clinics, will benefit from the continued availability of Rolvedon.
• Suppliers may be impacted by the company's reliance on single-source suppliers and the need to maintain a stable supply chain.
• Creditors will be interested in the company's cash flow generation and ability to meet its debt obligations.

Next Steps

• The company will present initial data from the Rolvedon same-day dosing trial at a medical conference later this year.
• Assertio will continue to focus on driving the financial performance of its key assets, generating cash flow, and identifying new assets.
• The company will host a conference call to discuss its second quarter 2024 financial results.

Key Dates

Keywords

Rolvedon, Indocin, pharmaceutical, net product sales, EBITDA, generic competition, cash flow, oncology, financial results, Assertio Holdings